Improving T cell therapy for pediatric brain tumors
Improving genetically engineered T cells for medulloblastomas
This study is testing a new treatment for kids with medulloblastoma by using specially modified immune cells to help them better fight the cancer, and it aims to make the treatment more effective and with fewer side effects than what’s currently available.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11035237 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy using genetically engineered T cells to target medulloblastoma, the most common brain tumor in children. The approach involves modifying the patient's own T cells to enhance their ability to recognize and attack cancer cells by targeting specific antigens found on these tumors. By using a mouse model, the researchers will investigate how to optimize T cell function in the challenging environment of brain tumors, which often suppress immune responses. This innovative method aims to provide a more effective treatment option with fewer long-term side effects compared to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with medulloblastoma who have not responded well to conventional treatments.
Not a fit: Patients with other types of brain tumors or those who are older than 11 years may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for medulloblastoma, improving survival rates and reducing long-term side effects for young patients.
How similar studies have performed: Previous research has shown success in using engineered T cells for treating other cancers, particularly leukemia, suggesting a promising potential for this approach in medulloblastoma.
Where this research is happening
Memphis, United States
- St. Jude Children's Research Hospital — Memphis, United States (Active)
Researchers
- Principal investigator: Krenciute, Giedre — St. Jude Children's Research Hospital
- Study coordinator: Krenciute, Giedre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.